Science 37 Wins 2026 BioTech Breakthrough Award for Clinical Trials Innovation

In a major recognition of innovation in healthcare, Science 37, based in Morrisville, North Carolina, has been awarded the prestigious title of "BioTechnology Innovation of the Year" at the 2026 BioTech Breakthrough Awards. This honor highlights the effectiveness of their Direct-to-Patient Site model, which is transforming how clinical trials are conducted and making them more accessible to patients nationwide.

Redefining Clinical Trials

Historically, participating in clinical trials required patients to travel to specific research facilities, often creating barriers for individuals who lived far from these sites. Science 37 is changing this narrative by offering a unified clinical research site that spans the entire country. This innovative approach enables pharmaceutical companies to widen their search for participants without investing in extensive physical infrastructure.

How Science 37 Works

Utilizing advanced medical oversight, Science 37 employs licensed investigators across all 50 states. Their specialized mobile nursing teams deliver research services directly to patients' homes. This model not only complements traditional clinical trial methods but also serves as a vital alternative that can significantly boost enrollment and patient involvement throughout the trial process.

Outstanding Results

A study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) showcased the impressive outcomes facilitated by Science 37's approach:

• Increased Enrollment: Science 37's trials saw an average of 150 participants enrolled per study, compared to the mere 26 participants at conventional research sites.
• Significant Impact: As a singular research entity, Science 37 accounted for 20-30% of total study enrollment in the trials evaluated.
• High Retention Rates: Completion rates at Science 37 exceeded industry benchmarks by over 50%.
• Diverse Representation: The model achieved better representation of women and Black participants, addressing the lack of diversity in clinical trials.

To date, Science 37 has conducted over 200 clinical trials, covering all phases from I to IV and including observational studies. They have successfully executed more than 14,000 in-home clinical visits and have passed five Phase 3 FDA inspections, each resulting in a No Action Indicated (NAI) with no Form 483 observations, underscoring their adherence to stringent regulatory and quality standards.

Vision for the Future

"Science 37 is addressing one of the enduring challenges in clinical research: the belief that patients must commute to a physical location to participate in trials," said Bryan Vaughn, Managing Director of BioTech Breakthrough. "By merging nationwide access with centralized oversight and top-tier clinical operations, they illustrate how innovation can extend the reach of clinical trials without compromising quality."

As the landscape of clinical development evolves, Science 37 remains committed to refining its direct-to-patient model across different therapeutic areas and populations. Their vision is clear: to make clinical research accessible to everyone, independent of their geographical location.

For more information, please visit www.science37.com.